- |||||||||| CPV-104 / Eleva, Undisclosed factor H therapeutic / Eleva
Moss-Produced Human Factor H (CPV-104): Pioneering Rebalancing Therapies for Kidney Complement Disorders (Exhibit Hall, Convention Center) - Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_4209;
By optimizing dosing intervals and exploring s.c. administration, FH availability was significantly improved in conjunction with sustained reduction of glomerular C3 deposits in preclinical models. These findings provide valuable insights into the clinical translation of CPV-104 as a new therapeutic strategy for complement-mediated renal diseases, enabling physiological complement functionality.
- |||||||||| Undisclosed factor H therapeutic / Eleva
Journal: Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity. (Pubmed Central) - May 27, 2024
Furthermore, CPV-104 showed comparable functionality to serum-derived FH in vitro, as well as similar performance in ex vivo assays involving samples from patients with atypical hemolytic uremic syndrome, C3 glomerulopathy and paroxysomal nocturnal hematuria. CPV-104 - the human FH analog expressed in moss - will therefore allow the treatment of complement-associated human diseases by rebalancing instead of inhibiting the complement cascade.
- |||||||||| factor H / Eleva, Soliris (eculizumab) / AstraZeneca
Journal: An Interdisciplinary Diagnostic Approach to Guide Therapy in C3 Glomerulopathy. (Pubmed Central) - Jun 14, 2022
Such a combined diagnostic approach was used here for a 42-year-old female patient with a novel mutation in the Factor H gene, C3 glomerulopathy and signs of chronic endothelial damage. We present here an approach that might in future help to guide therapy of renal diseases with relevant complement activation, especially since diverse new anti-complement agents are under clinical investigation.
|
